456 related articles for article (PubMed ID: 6209007)
21. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
22. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
23. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.
Prokocimer M; Modan M; Rusoshansky S; Bairey O; Shaklai M
Anticancer Res; 1989; 9(4):1233-5. PubMed ID: 2479327
[TBL] [Abstract][Full Text] [Related]
24. Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B).
Sawada U; Yamazaki T; Suzuki K; Ashiya M; Satou Y; Hirano H; Tsuboi I; Sakuma A; Kura Y; Kouda K
Int J Hematol; 1992 Aug; 56(1):59-66. PubMed ID: 1382663
[TBL] [Abstract][Full Text] [Related]
25. [CAMBO-VIP for advanced diffuse large cell lymphoma (LSG classification)--a long-term follow-up study].
Okamoto M; Maruyama F; Tsuzuki M; Nomura T; Miyazaki H; Wakita M; Kojima H; Sobue R; Matsui T; Ino T
Gan To Kagaku Ryoho; 1994 Jan; 21(1):67-73. PubMed ID: 7507314
[TBL] [Abstract][Full Text] [Related]
26. [Provisional treatment results of intensive combination chemotherapy (m-BACOD) in non-Hodgkin lymphoma of intermediate and high malignancy].
Knecht H; Streuli RA; Odermatt BF; Rhyner K
Schweiz Med Wochenschr; 1987 Dec; 117(50):2038-41. PubMed ID: 2448874
[TBL] [Abstract][Full Text] [Related]
27. [M-BACOD in advanced case of non-Hodgkin's lymphoma].
Itami J; Ogata H; Shimizu K; Nemoto K; Yasuda S; Yoshida H; Mikata A; Arimizu N
Gan No Rinsho; 1990 Mar; 36(4):499-504. PubMed ID: 1690824
[TBL] [Abstract][Full Text] [Related]
28. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ
Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329
[TBL] [Abstract][Full Text] [Related]
29. MACOP-B treatment for intermediate and high-grade non-Hodgkin's lymphomas at diagnosis and in relapse.
Tarella C; Gallo E; Ferrero D; Badoni R; Carlesso N; Caracciolo D; Pileri A
Haematologica; 1990; 75(2):149-54. PubMed ID: 1694155
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of primary mediastinal large B-cell lymphomas].
Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
[TBL] [Abstract][Full Text] [Related]
31. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI
Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
[TBL] [Abstract][Full Text] [Related]
32. Primary chemotherapy for localized non-Hodgkin's lymphomas with diffuse histologic characteristics. Preliminary report of a prospective study.
Gomez GA; Reddy S; Krishnamsetty RM; Barcos M; Nava H; Han T; Ozer H; Henderson ES
Arch Intern Med; 1986 Sep; 146(9):1785-8. PubMed ID: 3489446
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of medium and highly malignant non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone and bleomycin (protocol MACOP-B)].
Pittrová H; Koza V; Vozobulová V; Cetkovský P; Skopek P; Jungerová J; Cepelák V
Vnitr Lek; 1989 Dec; 35(12):1177-82. PubMed ID: 2483776
[TBL] [Abstract][Full Text] [Related]
34. Methotrexate-leucovorin factor rescue regimens in diffuse large cell lymphoma.
Skarin AT; Canellos GP
NCI Monogr; 1987; (5):71-6. PubMed ID: 3501548
[TBL] [Abstract][Full Text] [Related]
35. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
36. Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma.
Niitsu N; Okamoto M; Aoki S; Okumura H; Yoshino T; Miura I; Hirano M
Ann Hematol; 2006 Jun; 85(6):374-80. PubMed ID: 16518603
[TBL] [Abstract][Full Text] [Related]
37. 5-year survey of methotrexate, cyclophosphamide (Endoxan), and vincristine (MEV) therapy for advanced non-Hodgkin's lymphomas.
Lauria F; Baccarani M; Fiacchini M; Frezza R; Gobbi M; Tura S
Cancer Treat Rep; 1978 Aug; 62(8):1193-7. PubMed ID: 688255
[TBL] [Abstract][Full Text] [Related]
38. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
[TBL] [Abstract][Full Text] [Related]
39. [Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma].
Sampi K; Honda T; Hattori M; Takayama S
Gan To Kagaku Ryoho; 1983 May; 10(5):1266-71. PubMed ID: 6191677
[TBL] [Abstract][Full Text] [Related]
40. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
